SEC Company Response from Oncocyte Corp (OCX) (CIK 0001642380) (IMDX) — Jun 17, 2019
Oncocyte Corp (OCX) (CIK 0001642380)
Date: June 17, 2019 · CIK: 0001642380 · Accession: 0001493152-19-009263
AI Filing Summary & Sentiment
File numbers found in text: 333-231980
Letter
Re: OncoCyte Corporation
June 17, 2019
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
F Street, NE
Washington, DC 20549-4561
Attn: Donald Field
Registration Statement on Form S-3
File No. 333-231980
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, OncoCyte Corporation hereby requests that the Securities and Exchange Commission accelerate the effectiveness of the above-referenced Registration Statement to 4:00 p.m., Eastern Time, on Tuesday, June 18, 2019, or as soon thereafter as practicable.
Thank you for your assistance. Should you have any questions, please contact Andrew Ledbetter of DLA Piper LLP (US) at (206) 839-4845.
Very
truly yours,
OncoCyte
Corporation
Show Raw Text
CORRESP
1
filename1.htm
June
17, 2019
Via
EDGAR
Securities
and Exchange Commission
Division
of Corporation Finance
100
F Street, NE
Washington,
DC 20549-4561
Attn:
Donald
Field
Re:
OncoCyte
Corporation
Registration
Statement on Form S-3
File
No. 333-231980
Ladies
and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, OncoCyte Corporation hereby requests that
the Securities and Exchange Commission accelerate the effectiveness of the above-referenced Registration Statement to 4:00 p.m.,
Eastern Time, on Tuesday, June 18, 2019, or as soon thereafter as practicable.
Thank
you for your assistance. Should you have any questions, please contact Andrew Ledbetter of DLA Piper LLP (US) at (206) 839-4845.
Very
truly yours,
OncoCyte
Corporation
/s/
William Annett
William
Annett
President
and Chief Executive Officer